Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 26, 2007

Goodwin Biotechnology to Produce Neogenix’ mAb for Pancreatic Cancer

  • Neogenix Oncology and Goodwin Biotechnology entered into an agreement for process development and manufacturing of Neogenix’ first therapeutic product. NPC-1C is a mAb intended for the treatment of advanced pancreatic cancer.

    Neogenix expects to begin Phase I and Phase II trials of the product during the first half of 2008.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.